phase1-2 · 2024
MSC and cell secretome in atopic dermatitis
Multiple institutions (indexed in PubMed)
Small studies report reduced severity scores in some patients; better-controlled studies are needed for confirmation.
PubMedAdvanced search
Search the evidence register: research titles, expert names and patent numbers
Enter a research title, an expert name, a programme code such as ADSTEM, or a patent number such as 10-1172638. Results appear as cards with source links you can check yourself.
21 records for “atopic dermatitis”
Research records
Each record states the study stage, institution and source link.
phase1 · 2024
Early-stage MSC research in psoriasis
Case series and phase 1 studies
PASI reductions reported in small numbers of patients; must still be compared with far better-evidenced biologics.
PubMedphase2 · 2024
ADSTEM Inj.: clinical trials in atopic dermatitis (hospital information)
EHL BIO with five Korean hospitals including Chung-Ang University Hospital (as stated by the hospital)
The hospital's affiliated research centre states Phase 1 completed in 2017, Phase 2 completed in 2023 and a Phase 3 IND submitted in 2024. No accessible peer-reviewed results confirm efficacy, and this is not approved treatment in Thailand.
EHL BIO (research page)review · 2024
Systematic reviews: MSC for knee osteoarthritis
Multiple institutions (indexed in PubMed)
Multiple studies report short- to medium-term improvement in pain and function; evidence of cartilage regeneration remains limited and methods vary widely.
PubMedphase2 · 2024
MSC administration in decompensated liver cirrhosis
Multiple institutions (indexed in PubMed)
Some studies report improved albumin and MELD scores over 6–12 months; results are inconsistent between studies and standard care is unchanged.
PubMedreview · 2023
Meta-analyses: cell therapy after myocardial infarction
Multiple institutions (indexed in PubMed)
Effects on ejection fraction are small and inconsistent, with no clear mortality benefit in large trials.
PubMedphase2 · 2025
MSC in autoimmune disease: research overview
Multiple institutions (indexed in PubMed)
The most advanced research is in graft-versus-host disease, lupus nephritis and fistulising Crohn's disease. Where products are approved, indications are very narrow.
ClinicalTrials.govphase1-2 · 2024
Cell therapy in spinal cord injury
Multiple institutions (PubMed)
Most studies are small and combined with intensive rehabilitation, making the cells' own contribution difficult to isolate.
PubMedphase3 · 2025
Randomised cell therapy studies in heart failure
Multiple institutions (indexed in PubMed)
Ejection fraction changes are small and inconsistent; some studies report reduced hospitalisation in high-inflammation subgroups.
PubMedphase1-2 · 2024
Intradiscal MSC injection
Multiple institutions (PubMed)
Acceptable safety and reduced pain scores in some groups; imaging changes remain inconsistent.
PubMedphase1-2 · 2025
Exosome and secretome studies in hair loss
Multiple institutions (PubMed)
Some small studies report short-term increases in hair density, but preparations and endpoints vary widely and no large placebo-controlled trial exists.
PubMedpreclinical · 2025
MSC and exosomes in neuropathic pain models
Multiple institutions (PubMed)
Reduced pain behaviour and glial inflammation in animal models; not confirmed in humans.
PubMedEHL BIO published papers
Titles listed on EHL BIO's research institute page, with PubMed lookup links.
19 Nov 2016
Human adipose tissue derived mesenchymal stem cells alleviate atopic dermatitis via regulation of B lymphocyte maturation
6 Nov 2018
Human Adipose Tissue Derived Mesenchymal Stem Cells Attenuate Atopic Dermatitis by Regulating the Expression of MIP2, miR122a-SOCS1 Axis, and Th1/Th2 Responses
Registered patents
A patent evidences intellectual-property registration, not treatment efficacy.
No. 10-2016-0139967
Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof
Registered 26 Oct 2016
Pharmaceutical composition for preventing or treating atopic disease, using cells cultured with a 15-PGDH inhibitor in PGE2-expressing cells or their culture (atopic dermatitis).
EHL BIO patent pageNo. 10-2018-0030906
Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof
Registered 16 Mar 2018
Pharmaceutical composition for preventing or treating atopic disease (atopic dermatitis).
EHL BIO patent pageExperts and review teams
Published profiles contain only details checkable against public sources.
EHL BIO
EHL BIO Stem Cell Research Institute
Stem cell therapeutics research and development team
ADSTEM (atopic dermatitis), KDSTEM (chronic kidney disease), RASTEM (rheumatoid arthritis), PDSTEM (Parkinson's disease) and adipose-derived exosome programmes
EHL BIO — Stem cell treatmentEHL BIO
MD Hong-gi Lee (CEO)
Chief Executive Officer, EHLBIO Co., Ltd.
Direction of stem cell, immune cell and exosome therapeutics development
EHL BIO — CEO MessageEHL BIO
EHL BIO GMP Centre Quality Team
Manufacturing, quality control and cell banking
Class 100 clean facilities, cell banking systems and pre/post-cryopreservation quality control
EHL BIO — GMP centerEHL BIO
EHL BIO Immune Cell Research Team
Immune cell therapy research and immune cell banking
Keycell-IM programme (T, NK, iNKT and dendritic cells); the hospital's affiliated research centre states lung cancer as the preclinical target
EHL BIO — Immune Cell TherapeuticsEHL Thailand
EHL Thailand Medical Information Team
Writes and reviews disease pages and stem cell topics
Evidence levels, regulatory status, and separating hospital information from medical information
An EHL doctor or scientist? Submit your real biography and licence for the register.
Submit expert profile